TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Clinical trials for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOID CARDIOMYOPATHY trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Heart drug tafamidis shows promise in korean ATTR-CM patients
Disease control CompletedThis study looked at how well the drug tafamidis works for Korean patients with a rare heart condition called ATTR-CM. Researchers tracked 13 patients who were already taking the drug to see if it improved their heart function, symptoms, and quality of life. The goal was to under…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Sponsor: Pfizer • Aim: Disease control
Last updated May 17, 2026 16:34 UTC
-
New heart drug safety checked in small indian study
Disease control CompletedThis study looked at the safety of a medicine called VyndaMx (tafamidis) for people with a rare heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). Six adults in India took the medicine by mouth, and doctors tracked any side effects for 6 months. The goal was t…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Sponsor: Pfizer • Aim: Disease control
Last updated May 12, 2026 13:43 UTC